VE-822
Detailed Description
VE-822, an analogue of VE-821 with increased potency and selectivity against ATR, increased solubility and good pharmacokinetic properties was shown to potently radiosensitise pancreatic cancer cell lines in vitro.VE-822 was the first selective ATR inhibitor to enter clinical development, and is now known as VX-970. In a recent study, published by Vertex Pharmaceuticals, VX-970 (VE-822) was shown to markedly sensitise a panel of non-small cell lung cancer cell lines, but not normal cells, to multiple DNA damaging drugs, namely cisplatin, oxaliplatin, gemcitabine, etoposide and SN38, the active metabolite of irinotecan.
- VE-822
View Contact Detail